TherapeuticsMD, Inc.
General ticker "TXMD" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $18.9M (TTM average)
TherapeuticsMD, Inc. follows the US Stock Market performance with the rate: 24.0%.
Estimated limits based on current volatility of 2.4%: low 2.19$, high 2.28$
Factors to consider:
- Total employees count: 1 as of 2025
- Top business risk factors: Going concern doubt, Operational and conduct risks, Losses/no profitability, Management transitions frequent, Intellectual property risks
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.08$, 2.41$]
- 2026-12-31 to 2027-12-31 estimated range: [0.96$, 2.18$]
Financial Metrics affecting the TXMD estimates:
- Positive: with PPE of -33.2 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Positive: 6.77 < Operating cash flow per share per price, % of 12.52
- Positive: Investing cash flow per share per price, % of 0 > -0.64
- Positive: -3.10 < Return on assets ratio (scaled to [-100,100]) of -1.70
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of -0.31 <= -0.14
- Positive: Shareholder equity ratio, % of 71.37 > 63.63
- Positive: Inventory ratio change, % of 0 <= 0
Short-term TXMD quotes
Long-term TXMD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.30MM | $1.76MM | $3.02MM |
| Operating Expenses | $9.82MM | $6.52MM | $7.41MM |
| Operating Income | $-8.52MM | $-4.76MM | $-4.39MM |
| Non-Operating Income | $0.78MM | $2.42MM | $3.74MM |
| Income(Loss) | $-7.74MM | $-2.34MM | $-0.65MM |
| Taxes | $-0.04MM | $-0.03MM | $0.00MM |
| Other Income(Loss) | $-2.58MM | $0.13MM | $0.08MM |
| Net Income(Loss)* | $-10.28MM | $-2.18MM | $-0.57MM |
| Stockholders Equity | $29.29MM | $27.37MM | $26.88MM |
| Assets | $43.31MM | $38.82MM | $37.66MM |
| Operating Cash Flow | $-23.08MM | $0.73MM | $2.42MM |
| Capital expenditure | $48.14MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-25.06MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $3.15MM | $0.00MM | $0.00MM |
| Earnings Per Share** | $-0.98 | $-0.19 | $-0.05 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.